Who Paid My Doc
Harikrashna Bhatt
Endocrinology, Diabetes & Metabolism Riverside, RI Medical Doctor
NPI 1285765792 CMS profile 854336
375 Wampanoag Trl Ste 202B, Riverside, RI 02915
General payments
$60
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Harikrashna Bhatt of Riverside, RI is reported in the CMS Open Payments database as having received $60 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 8th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $60 | 1 |
Beside peers
- Harikrashna Bhatt
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Harikrashna Bhatt were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Harikrashna Bhatt | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $60 | $398 | $88–$1,981 | $132 |
| 2022 | $0 | $364 | $88–$1,568 | $149 |
| 2023 | $0 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 31 drugsPart D claims
1,256
Drug cost
$222,563
Branded share of claims
50.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 44 | $40,265 | |
| Jardiance Empagliflozin | Brand | 45 | $35,108 | |
| Trulicity Dulaglutide | Brand | 24 | $30,596 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 99 | $23,162 | |
| Humalog Kwikpen U-100 Insulin Lispro | Brand | 59 | $15,723 | |
| Tradjenta Linagliptin | Brand | 14 | $12,093 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 23 | $9,679 | |
| Testosterone | Generic | 60 | $6,691 | |
| Novolog Flexpen Insulin Aspart | Brand | 32 | $6,174 | |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 43 | $5,604 |
The 10 drugs with the highest cost, of 31 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 12 billing codesPaid by Medicare
$19,854
Medicare patients
154
Services billed
289
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 58% | |
| Arthritis | 54% | |
| Ischemic heart disease | 38% | |
| Chronic kidney disease | 38% | |
| Depression | 32% | |
| Osteoporosis | 27% | |
| COPD | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Rhode Island
Robert Dobrzynski
Endocrinology, Diabetes & Metabolism · Providence, RI
Frank D'alessandro
Endocrinology, Diabetes & Metabolism · North Providence, RI
Ricardo Correa Marquez
Endocrinology, Diabetes & Metabolism · East Providence, RI
Robert Smith
Endocrinology, Diabetes & Metabolism · Providence, RI
Sudhir Bansal
Endocrinology, Diabetes & Metabolism · Warwick, RI
Joseph Tucci
Endocrinology, Diabetes & Metabolism · Providence, RI
Related records
Endocrinology, Diabetes & Metabolism in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.